Kenya Elevates Regulatory Framework to Combat Substandard and Falsified Medical Products
In a significant move to bolster public health and national security, Kenya has formally established an Interministerial Steering Committee (ISC) tasked with the rigorous implementation of its National Action Plan against Substandard and Falsified (SF) Medical Products. The inauguration of this high-level committee by Health Cabinet Secretary Hon. Aden Duale signals a strengthened, coordinated approach to tackling the pervasive threat of unsafe medicines through enhanced regulation and enforcement.
The ISC will function as the principal governance body for the National Action Plan, providing strategic direction, policy oversight, and crucial inter-agency coordination. By bringing together institutions with overlapping mandates, the committee aims to foster robust collaboration in the prevention, detection, investigation, and response to SF medical products. This unified effort is designed to address critical policy, legal, operational, regulatory, and resource challenges that have historically hampered effective action.
According to statements from the Ministry of Health, substandard and falsified medical products represent a grave threat to public health, the economy, and national security. These illicit products contribute to treatment failures, exacerbate antimicrobial resistance, and cause preventable deaths. Furthermore, they erode public trust in the healthcare system and jeopardise the successful rollout of national health initiatives such as Taifa Care and Universal Health Coverage (UHC).
Cabinet Secretary Duale underscored the necessity of a comprehensive, whole-of-government strategy to combat this menace. This approach necessitates close collaboration among regulatory agencies, law enforcement bodies, border control authorities, county governments, healthcare professionals, manufacturers, distributors, development partners, and the public.
Kenya has demonstrably been reinforcing its pharmaceutical regulatory systems. Between 2021 and 2025, the Pharmacy and Poisons Board (PPB) recorded 1,413 product quality complaints, orchestrated 99 product recalls, received 32,833 adverse drug reaction reports, and issued 18 public alerts concerning suspected falsified medicines. More recently, the PPB has conducted 58 product recalls and issued 14 rapid alerts on falsified medical products, reflecting an increasingly vigilant, transparent, and responsive regulatory environment.
Enforcement actions have also been intensified, leading to the closure of over 200 non-compliant pharmaceutical premises and resulting in arrests and prosecutions of individuals involved in the illegal trade of medical products.
Reaffirming the government’s unwavering commitment to safeguarding the integrity of the pharmaceutical supply chain, the Ministry of Health will continue its collaboration with the World Health Organization (WHO) and other international partners. These efforts are focused on enhancing regulatory capacity, strengthening post-market surveillance, improving intelligence sharing, advancing digital traceability, and bolstering enforcement in alignment with international best practices. The ultimate goal is to ensure that all Kenyans have access to safe, quality, effective, and affordable medicines.
The inauguration ceremony was attended by key stakeholders, including the Council of Governors Vice Chairperson and Governor of Tharaka Nithi County, H.E. Muthomi Njuki; Council of Governors Chief Executive Officer Ms. Mary Mwiti; Pharmacy and Poisons Board Chairperson Dr. John Munyu; Pharmacy and Poisons Board Chief Executive Officer Dr. Ahmed Mohamed; representatives from the World Health Organization (WHO) and IGAD, alongside senior government officials, development partners, and other stakeholders dedicated to protecting Kenya’s pharmaceutical supply chain.
